MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

21.47 0.05

Buy Sell

Overview

Share price change

24h

Current

Min

21.46

Max

21.47

Key metrics
By Trading Economics
Income	-1.6M -21M
Sales	14M 54M
Profit margin	-39.611
Employees	178
EBITDA	-3.8M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-2.84% downside

Dividends
By Dow Jones
Next Earnings	5 May 2026

Market Stats
By TradingEconomics
Market Cap	1B 2.2B
Previous open	21.42
Previous close	21.47

News Sentiment

By Acuity

50%

168 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Apr 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 Apr 2026, 18:15 UTC

Major News Events

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 Apr 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 Apr 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 Apr 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 Apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 Apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 Apr 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 Apr 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 Apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Apr 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 Apr 2026, 20:11 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 Apr 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

17 Apr 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 Apr 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 Apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 Apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 Apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 Apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 Apr 2026, 18:57 UTC

Major News Events

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 Apr 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 Apr 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB 2026 Rev Guidance Unchanged

17 Apr 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 Apr 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 Apr 2026, 18:14 UTC

Market Talk

Major News Events

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 Apr 2026, 18:00 UTC

Major News Events

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 Apr 2026, 18:00 UTC

Major News Events

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 Apr 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 Apr 2026, 17:26 UTC

Market Talk

Earnings

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

-2.84% downside

12 Months Forecast

Average 20.86 USD -2.84%

High 21.5 USD

Low 17 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

168 / 348 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.